A high proportion of depressed patients fail to respond to antidepressant drug treatment.
Treatment‐resistant depression (TRD) is a major challenge for the psychopharmacology of …

Background The use of ketamine for depression has increased rapidly in the past decades.
Ketamine is often prescribed as an add-on to other drugs used in psychiatric patients, but …

Patients with major depressive disorder (MDD) often exhibit an inadequate treatment
response or failure to achieve remission following treatment with antidepressant drugs …

Introduction Intranasal (IN) esketamine represents an innovative treatment for individuals
with treatment resistant depression and depression with suicidal ideation and behavior …

Introduction Due to favorable antidepressant (AD) efficacy and tolerability, selective-
serotonin reuptake inhibitors (SSRIs) are consistently recommended as substances of first …

Psychedelic treatments for mental health conditions pose challenges for informed consent |
Nature Medicine Skip to main content Thank you for visiting nature.com. You are using a …

Since the mid 1980's, there has been an increased focus on the side effects of
benzodiazepines (GABA enhancers), and as a result there has been a decrease in their use …

Intranasal esketamine for treatment-resistant depression has been introduced and approved
by the FDA and EMA in 2019 and 2020, respectively. Since then, the administration …

Antidepressant doses of ketamine rapidly facilitate synaptic plasticity and modify neuronal
function within prefrontal and hippocampal circuits. However, most studies have …

Conventional antidepressants that target monoaminergic receptors require several weeks to
be efficacious. This lag represents a significant problem in the currently available treatments …